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Introduction	  
In	  the	  United	  States,	  women	  receive	  on	  average	  1.3	  prescriptions	  from	  each	  physician	  visit	  during	  pregnancy	  (Lee	  et	  al.,	  2006).	  Despite	  the	  considerable	  use	  of	  medications	  to	  manage	  and	  treat	  chronic	  and	  emergent	  conditions,	  the	  U.S.	  Food	  and	  Drug	  Administration	  (FDA)	  has	  approved	  only	  thirteen	  medications	  for	  use	  by	  pregnant	  women	  (Greenberg	  et	  al.,	  2011).	  This	  incongruity	  is	  largely	  a	  product	  of	  the	  complex	  problem	  of	  insufficient	  inclusion	  of	  pregnant	  women	  in	  biomedical	  research.	  This	  paper	  explores	  the	  consequences	  of	  exclusion,	  arguing	  that	  low-­‐income	  populations	  of	  color	  are	  disproportionately	  burdened	  by	  both	  the	  insufficient	  inclusion	  of	  pregnant	  women	  in	  research	  and	  the	  resulting	  information	  gap	  on	  maternal-­‐fetal	  drug	  safety	  and	  efficacy.	  
To	  provide	  some	  context,	  the	  paper	  will	  begin	  by	  providing	  background	  on	  the	  history	  of	  women	  and	  biomedical	  research.	  In	  the	  following	  section,	  the	  scope	  of	  the	  problem	  will	  be	  outlined,	  followed	  by	  discussion	  of	  consequences	  for	  low-­‐income	  persons	  of	  color.	  The	  final	  section	  will	  recognize	  both	  legal	  and	  non-­‐legal	  challenges	  while	  presenting	  various	  recommendations	  for	  action.	  	  
Background	  	  
Although	  over	  half	  of	  all	  current	  research	  participants	  are	  women,	  this	  has	  not	  always	  been	  the	  case.	  Prior	  to	  the	  1990s,	  human	  subject	  research	  was	  conducted	  almost	  exclusively	  on	  white	  men.	  There	  are	  various	  alleged	  justifications	  for	  this	  exclusion	  (Dresser,	  1992).	  For	  one,	  it	  is	  likely	  that	  to	  some	  extent,	  there	  was	  belief	  in	  
	   3	  
a	  human	  norm,	  and	  that	  women	  and	  minorities	  did	  not	  differ	  enough	  from	  the	  norm	  for	  their	  exclusion	  to	  present	  a	  concern	  for	  generalizability	  of	  results.	  Conversely	  some,	  epidemiologists	  argued	  that	  studying	  a	  more	  homogenous	  population	  would	  produce	  cleaner,	  simpler	  data	  that	  would	  make	  it	  easier	  to	  attribute	  effects	  to	  the	  experimental	  intervention.	  Third,	  a	  type	  of	  paternalism	  or	  chivalry	  may	  have	  been	  at	  play,	  as	  men	  attempted	  to	  shield	  women	  from	  the	  real	  or	  perceived	  risks	  of	  participation	  in	  research	  studies.	  In	  addition,	  there	  has	  long	  been,	  and	  continues	  to	  be,	  concern	  for	  women	  and	  their	  potential	  offspring	  should	  they	  become	  pregnant	  during	  the	  course	  of	  the	  study	  (Dresser,	  1992).	  	  What	  was	  not	  acknowledged,	  however,	  was	  that	  “protecting”	  women	  from	  research	  risks	  meant	  that	  they	  also	  weren’t	  afforded	  the	  direct	  benefits	  of	  either	  participation	  or	  data	  that	  could	  reasonably	  inform	  their	  care	  as	  a	  population.	  
The	  movement	  fighting	  for	  increased	  inclusion	  of	  women	  in	  health	  research	  began	  to	  take	  ground	  in	  the	  mid-­‐1980s.	  	  During	  that	  time,	  AIDS	  activists	  working	  towards	  increasing	  access	  to	  experimental	  AIDS	  therapies	  offered	  the	  first	  formal	  challenge	  to	  the	  protectionist	  policies	  of	  preceding	  decades.	  These	  activists	  called	  for	  earlier	  release	  of	  AIDS	  drugs	  in	  the	  development	  process.	  As	  a	  result	  of	  these	  efforts	  the	  FDA	  issued	  regulations	  expanding	  access	  to	  experimental	  drugs	  used	  to	  treat	  life-­‐threatening	  illnesses.	  The	  success	  of	  these	  activists	  energized	  the	  women’s	  health	  movement	  (Mastroianni	  et	  al.,	  1994).	  	  
By	  this	  time,	  women	  had	  gained	  enough	  political	  power	  to	  allow	  the	  women’s	  movement	  to	  forcefully	  confront	  the	  science	  and	  health	  bureaucracy.	  At	  the	  time,	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the	  FDA	  had	  a	  policy	  that	  restricted	  women	  of	  childbearing	  potential	  from	  participating	  in	  clinical	  research	  (HEW,	  1977).	  The	  policy	  was	  largely	  in	  response	  to	  the	  thalidomide	  and	  diethylstilbestrol	  tragedies	  from	  earlier	  in	  the	  century.	  The	  women’s	  health	  movement	  began	  to	  take	  action	  by	  supporting	  female	  candidates,	  fund-­‐raising	  for	  women’s	  issues	  and	  forming	  interest	  groups	  to	  educate	  themselves	  and	  pressure	  unresponsive	  bureaucrats	  (Mastroianni	  et	  al.,	  1994).	  Largely	  in	  response	  to	  this	  pressure,	  the	  U.S.	  Preventive	  Services	  Task	  Force	  on	  Women’s	  Health	  Issues	  published	  a	  report,	  which	  concluded	  that:	  
The	  historical	  lack	  of	  research	  focus	  on	  women’s	  health	  concerns	  has	  compromised	  the	  
quality	  and	  health	  information	  available	  to	  women	  as	  well	  as	  the	  health	  care	  they	  
receive	  (HHS,	  1985).	  	   The	  recommendations	  that	  accompanied	  the	  report	  provoked	  the	  National	  Institute	  of	  Health	  (NIH),	  an	  agency	  of	  the	  U.S.	  Department	  of	  Health	  and	  Human	  Services,	  to	  announce	  a	  new	  policy	  in	  1986.	  The	  policy	  urged	  funding	  applicants	  to	  include	  women	  in	  clinical	  research	  and	  evaluate	  gender	  differences	  in	  their	  findings.	  In	  addition,	  the	  policy	  stated	  that	  applicants	  should	  provide	  a	  clear	  rationale	  for	  proposed	  exclusion	  of	  women	  (Mastroianni	  et	  al.,	  1994).	  A	  few	  years	  later	  in	  1990,	  the	  General	  Accounting	  Office	  (GAO,	  name	  changed	  to	  Government	  Accountability	  Office	  in	  2004)	  released	  a	  report	  in	  which	  it	  evaluated	  the	  efficacy	  of	  the	  NIH	  policy.	  The	  report	  stated	  the	  decentralized	  and	  un-­‐automated	  recordkeeping	  at	  the	  NIH	  had	  prevented	  GAO	  from	  systematically	  evaluating	  the	  effectiveness	  of	  the	  policy,	  and	  that	  the	  policy	  had	  not	  been	  sufficiently	  disseminated	  either	  internally	  or	  to	  prospective	  grant	  applicants	  and	  therefore	  probably	  had	  not	  been	  implemented	  consistently,	  if	  at	  all	  (IOM,	  2010).	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   Following	  the	  release	  of	  the	  1990	  GAO	  report	  many	  practices	  and	  policies	  that	  had	  once	  been	  presented	  as	  protective	  were	  re-­‐labeled	  as	  paternalistic	  and	  discriminatory.	  	  Largely	  in	  response	  to	  the	  report,	  the	  director	  of	  the	  NIH	  announced	  the	  creation	  of	  the	  Office	  of	  Research	  on	  Women’s	  Health	  (ORWH)	  (statutorily	  authorized	  June	  1993).	  The	  ORWH	  was	  given	  a	  three-­‐part	  mandate	  (Mastroianni	  et	  al.,	  1994):	  
1. To	  strengthen	  and	  enhance	  research	  related	  to	  diseases,	  disorders	  and	  conditions	  that	  affect	  women	  and	  to	  ensure	  that	  the	  research	  conducted	  and	  supported	  by	  NIH	  adequately	  addresses	  issues	  regarding	  women’s	  health.	  2. To	  ensure	  that	  women	  are	  appropriately	  represented	  in	  biomedical	  and	  behavioral	  research	  studies	  supported	  by	  NIH.	  3. To	  foster	  the	  increased	  enrollment	  in	  biomedical	  research	  –	  especially	  in	  pivotal	  decision-­‐making	  roles	  within	  both	  clinical	  medicine	  and	  the	  research	  environment.	  	  The	  legislation	  that	  eventually	  authorized	  the	  ORWH	  as	  a	  permanent	  entity	  began	  as	  a	  part	  of	  the	  Women’s	  Health	  Equity	  Act	  (WHEA).	  WHEA	  was	  an	  omnibus	  legislative	  package	  that	  was	  first	  introduced	  in	  1990	  and	  reintroduced	  a	  year	  later.	  It	  contained	  twenty-­‐two	  bills	  that	  addressed	  research,	  care	  and	  prevention	  issues	  in	  women’s	  health.	  Six	  of	  these	  provisions	  (including	  the	  one	  permanently	  authorizing	  the	  ORWH)	  were	  passed	  during	  the	  1991-­‐1992	  legislative	  year	  via	  incorporation	  into	  the	  NIH	  Revitalization	  Act.	  One	  of	  the	  provisions	  included	  a	  policy	  regarding	  inclusion	  of	  women	  and	  racial/ethnic	  minorities	  into	  NIH-­‐sponsored	  or	  -­‐funded	  clinical	  research.	  Although	  the	  NIH	  Revitalization	  Act	  passed	  both	  the	  Senate	  and	  House	  of	  Representatives,	  it	  was	  vetoed	  by	  President	  Bush	  Sr.	  Fortunately,	  the	  bill	  was	  reintroduced	  with	  strong	  support	  from	  the	  Senate	  Majority	  Leader	  in	  January	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1993	  and	  President	  Clinton	  signed	  the	  NIH	  Revitalization	  Act	  into	  law	  June	  10,	  1993	  (Mastroianni	  et	  al.,	  1994;	  IOM	  2010).	  The	  1994	  NIH	  guidelines	  state	  that:	  
	  [I]n	  addition	  to	  the	  continuing	  inclusion	  of	  women	  and	  biomedical	  and	  behavioral	  
research	  involving	  human	  subjects,	  the	  NIH	  must:	  ensure	  that	  women	  and	  members	  of	  
minorities	  and	  their	  subpopulations	  are	  included	  in	  all	  human	  subject	  research;	  for	  
Phase	  III	  clinical	  trials,	  ensure	  that	  women	  and	  minorities	  and	  their	  subpopulations	  
must	  be	  included	  such	  that	  valid	  analyses	  of	  differences	  in	  intervention	  effect	  can	  be	  
accomplished;	  not	  allow	  cost	  as	  an	  acceptable	  reason	  for	  excluding	  these	  groups;	  and,	  
initiate	  programs	  and	  support	  for	  outreach	  efforts	  to	  recruit	  these	  groups	  into	  clinical	  
studies	  (NIH,	  1994).	  	  In	  addition	  to	  the	  NIH	  policy	  change,	  other	  events	  stirred	  the	  public	  sentiment	  about	  paternalism,	  protectionism	  and	  discrimination.	  In	  1991,	  the	  U.S.	  Supreme	  Court	  heard	  International	  Union,	  UAW	  v.	  Johnson	  Controls,	  a	  case	  involving	  a	  battery	  manufacturing	  company	  that	  had	  a	  workplace	  policy	  that	  barred	  women	  of	  reproductive	  age	  from	  performing	  certain	  jobs	  because	  of	  potential	  risk	  of	  fetal	  injury	  and	  subsequent	  issues	  of	  liability.	  The	  court	  ruled	  that	  the	  policy	  constituted	  sex	  discrimination	  and	  was	  therefore	  unconstitutional	  (IOM,	  2010).	  In	  1992,	  GAO	  released	  a	  second	  report	  addressing	  the	  inclusion	  of	  women	  in	  clinical	  studies.	  The	  report	  examined	  FDA	  policies	  and	  the	  pharmaceutical	  industry’s	  practices	  regarding	  experimental	  drug	  testing	  in	  women.	  The	  report	  concluded	  that	  although	  women	  were	  included	  in	  most	  of	  the	  drug	  studies	  reported,	  “for	  more	  than	  60	  percent	  of	  the	  drugs,	  the	  representation	  of	  women	  in	  the	  test	  population	  was	  less	  than	  the	  representation	  of	  women	  in	  the	  population	  with	  the	  corresponding	  disease”	  (GAO,	  1992).	  In	  addition,	  GAO	  noted	  that	  even	  when	  women	  were	  included,	  the	  data	  was	  often	  not	  analyzed	  to	  determine	  whether	  women’s	  responses	  differed	  from	  those	  of	  men.	  The	  report	  recommended	  that	  the	  FDA	  ensure	  that	  pharmaceutical	  companies	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consistently	  include	  “sufficient	  numbers	  of	  women	  in	  drug	  testing	  to	  identify	  gender-­‐related	  differences”	  (GAO,	  1992).	  	  
In	  March	  of	  1993,	  the	  FDA	  announced	  that	  it	  would	  lift	  the	  1977	  restrictions	  on	  the	  inclusion	  of	  women	  of	  childbearing	  potential	  in	  early	  stages	  of	  clinical	  trials,	  including	  pharmacology	  studies	  and	  early	  therapeutic	  studies.	  The	  revised	  policy	  formalized	  the	  FDA’s	  expectations	  regarding	  analysis	  of	  clinical	  data	  by	  gender,	  assessment	  of	  potential	  pharmacokinetic	  differences	  between	  genders,	  and	  where	  appropriate,	  assessment	  of	  pharmacodynamics	  differences	  and	  recommendations	  for	  additional	  studies	  on	  women	  (FDA,	  2009).	  	  In	  1994,	  offices	  of	  women’s	  health	  were	  established	  in	  the	  FDA	  and	  the	  Centers	  for	  Disease	  Control	  and	  Prevention	  (CDC)	  (IOM,	  2010).	  	  
Despite	  ostensible	  progress,	  in	  2000	  GAO	  issued	  a	  follow	  up	  audit	  of	  NIH	  that	  concluded	  that	  although	  women	  were	  in	  clinical	  trials	  at	  rates	  proportional	  to	  their	  numbers	  in	  the	  general	  population,	  “NIH	  has	  made	  less	  progress	  in	  implementing	  the	  requirement	  that	  certain	  clinical	  trials	  be	  designed	  and	  carried	  out	  to	  permit	  valid	  analysis	  by	  sex,	  which	  could	  reveal	  whether	  interventions	  affect	  women	  and	  men	  differently”	  (GAO,	  2000).	  In	  addition,	  the	  GAO	  audit	  of	  FDA	  records	  in	  2001	  revealed	  that	  eight	  of	  the	  last	  ten	  drugs	  withdrawn	  from	  market	  had	  caused	  more	  adverse	  effects	  on	  women	  than	  in	  men	  (IOM,	  2010).	  The	  final	  report	  revealed	  that	  of	  study	  documents	  examined,	  30	  percent	  failed	  to	  fulfill	  requirements	  for	  presentation	  of	  outcome	  data	  by	  sex	  and	  almost	  40	  percent	  did	  not	  include	  required	  demographic	  information	  (IOM,	  2010).	  In	  2001,	  NIH	  updated	  its	  policy	  on	  the	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inclusion	  of	  women	  and	  minorities	  as	  subjects	  in	  clinical	  research.	  The	  amended	  policy	  provides	  additional	  guidance	  on	  reporting	  analyses	  of	  sex/gender	  and	  racial/ethnic	  groups,	  particularly	  in	  Phase	  III	  clinical	  trials,	  so	  as	  to	  examine	  the	  differential	  effects	  on	  such	  groups	  (HHS,	  2001).	  
More	  recently,	  the	  Patient	  Protection	  and	  Affordable	  Care	  Act	  (PPACA,	  2010)	  formally	  codified	  the	  Offices	  of	  Women’s	  Health	  within	  Health	  and	  Human	  Services	  (HHS)	  and	  established	  Offices	  of	  Women’s	  Health	  in	  the	  director’s	  office	  of	  the	  Agency	  for	  Healthcare	  Research	  and	  Quality	  (AHRQ),	  CDC,	  FDA,	  Health	  Resources	  and	  Services	  Administration	  (HRSA)	  and	  the	  Substance	  Abuse	  and	  Mental	  Health	  Services	  Administration.	  In	  addition,	  PPACA	  formally	  established	  a	  HHS	  Coordinating	  Committee	  on	  Women’s	  Health	  and	  the	  National	  Women’s	  Health	  Information	  Center.	  Each	  center	  was	  appropriated	  funds	  for	  FY	  2010-­‐2014	  (IOM,	  2010).	  
While	  the	  existence	  of	  federal	  policies	  and	  the	  formation	  of	  new	  offices	  of	  women’s	  health	  represent	  a	  significant	  progress	  with	  regards	  to	  inclusion	  of	  women	  in	  health	  research,	  thoughtful	  discussion	  about	  including	  pregnant	  women	  has	  lagged	  behind.	  Although	  women	  now	  make	  up	  the	  majority	  of	  participants	  in	  clinical	  research,	  many	  researchers	  and	  institutional	  review	  boards	  (IRBs)	  continue	  to	  regard	  pregnancy	  as	  near-­‐automatic	  cause	  for	  exclusion,	  regardless	  of	  costs	  of	  exclusion	  or	  the	  extent	  or	  likelihood	  of	  risks	  of	  participation	  (Lyerly,	  2008).	  This	  prompted	  the	  coming	  together	  of	  a	  group	  of	  physicians	  and	  ethicists	  to	  start	  a	  project	  called	  “The	  Second	  Wave:	  Towards	  the	  Responsible	  Inclusion	  of	  Pregnant	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Women	  in	  Research”	  (Greenwood,	  2011).	  The	  initiative	  is	  a	  collaborative	  academic	  effort	  between	  faculty	  at	  University	  of	  North	  Carolina	  at	  Chapel	  Hill,	  Georgetown	  University	  and	  Johns	  Hopkins	  University,	  to	  advocate	  for,	  and	  help	  find	  ethical	  and	  scientifically	  responsible	  solutions,	  for	  increasing	  the	  responsible	  inclusion	  of	  pregnant	  women	  (Second	  Wave	  Initiative,	  2012).	  	  	  
The	  following	  section	  will	  discuss	  some	  of	  the	  reasons	  why	  the	  underrepresentation	  of	  pregnant	  women	  in	  biomedical	  studies	  is	  problematic.	  
What’s	  the	  problem?	  
Pregnant	  women	  are	  physiologically	  different	  Physiologically,	  there	  are	  important	  differences	  between	  pregnant	  and	  non-­‐pregnant	  women	  (See	  Table	  1).	  These	  differences	  affect	  pharmacokinetics,	  or	  the	  handling	  of	  a	  drug	  by	  a	  body,	  which	  includes	  how	  the	  drug	  is	  absorbed,	  distributed	  and	  eliminated,	  and	  how	  these	  processes	  determine	  plasma	  concentrations	  of	  the	  drug.	  Pharmacokinetics	  is	  not	  only	  different	  between	  pregnant	  and	  non-­‐pregnant	  women,	  but	  these	  differences	  vary	  during	  the	  course	  of	  pregnancy.	  Lack	  of	  sufficient	  information	  about	  how	  pharmacokinetics	  of	  pregnant	  women	  affects	  drug	  metabolism	  and	  efficacy	  means	  physicians	  cannot	  be	  certain	  that	  they	  are	  prescribing	  safe	  and	  effective	  dosages	  of	  medications	  to	  pregnant	  women	  (Dawes	  et	  al.,	  2001).	  	  
CASE	  STUDY.	  During	  the	  height	  of	  the	  post-­‐	  September	  11	  anthrax	  scare,	  the	  American	  College	  of	  Obstetricians	  and	  Gynecologists	  recommended	  that	  pregnant	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women	  be	  treated	  with	  amoxicillin	  in	  the	  event	  of	  anthrax	  exposure.	  However,	  more	  recent	  pharmacokinetic	  research	  has	  indicated	  that	  the	  changes	  to	  kidney	  function	  during	  pregnancy	  make	  it	  impossible	  to	  give	  a	  pregnant	  woman	  a	  high	  enough	  dose	  of	  amoxicillin	  for	  it	  to	  be	  effective	  against	  anthrax	  (Andrew	  et	  al.,	  2007)	  Table	  1.	  Select	  physiological	  changes	  during	  pregnancy	  (Ciliberto	  et	  al.,	  1998;	  Witorsche,	  1995).	  Increased	  Cardiac	  Output	   During	  the	  first	  trimester,	  cardiac	  output	  is	  20-­‐40%	  higher	  than	  in	  the	  non-­‐pregnant	  state.	  	  
Increased	  Plasma	  Volume	  
Blood	  volume	  increases	  progressively	  from	  6-­‐8	  weeks	  gestation,	  and	  reaches	  a	  maximum	  at	  approximately	  32-­‐34	  weeks.	  The	  increase	  in	  plasma	  volume	  (40-­‐50%)	  is	  relatively	  greater	  than	  that	  of	  red	  cell	  mass	  (20-­‐30%)	  resulting	  in	  hemodilution	  and	  decrease	  in	  hemoglobin	  concentration.	  Decreased	  Gastric	  Emptying	  and	  Intestinal	  Transport	  
As	  the	  uterus	  expands,	  it	  puts	  increasing	  pressure	  on	  the	  stomach	  and	  intestines,	  causing	  a	  gradual	  displacement	  of	  stomach	  and	  intestines.	  By	  term,	  the	  stomach	  has	  fully	  rotated	  from	  a	  horizontal	  to	  a	  vertical	  position.	  	  
Increased	  Renal	  Excretion	   Renal	  plasma	  flow	  and	  glomerular	  filtration	  rate	  begin	  to	  increase	  progressively	  during	  the	  first	  trimester.	  At	  term,	  both	  are	  50-­‐60%	  higher	  than	  in	  the	  non-­‐pregnant	  state.	  
Hormones	   Hormonal	  fluctuations	  occur	  as	  pregnancy	  progresses	  from	  first	  to	  third	  trimester.	  The	  hormones	  that	  are	  largely	  affected	  include:	  estrogen,	  progesterone,	  human	  chorionic	  gonadotropin	  (hCG),	  human	  placental	  lactogen	  (hPL)	  and	  prolactin.	  	  	  
Concerns	  about	  fetal	  exposure	  A	  teratogen	  is	  any	  agent	  that	  acts	  to	  irreversibly	  alter	  growth,	  structure	  or	  function	  of	  a	  developing	  embryo	  or	  fetus.	  The	  risks	  and	  consequences	  of	  exposure	  to	  teratogenic	  agents	  are	  in	  part	  dependent	  on	  the	  stage	  of	  embryonic	  or	  fetal	  development.	  This	  is	  because	  the	  organ	  undergoing	  the	  most	  rapid	  cell	  division	  during	  teratogenic	  exposure	  is	  the	  organ	  most	  susceptible	  to	  disruption	  in	  development	  (Dawes,	  2001).	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In	  the	  United	  States	  approximately	  49	  percent	  	  (2001	  data	  is	  most	  recent	  available)	  of	  pregnancies	  are	  unintended,	  meaning	  they	  were	  mistimed	  or	  unplanned	  at	  the	  time	  of	  conception	  (CDC,	  2012).	  Without	  having	  engaged	  in	  pre-­‐pregnancy	  planning	  or	  having	  expectations	  of	  becoming	  pregnant,	  these	  women	  are	  less	  likely	  to	  know	  that	  they	  are	  pregnant	  until	  weeks	  or	  months	  into	  the	  pregnancy	  (Cheng,	  2009).	  Without	  knowledge	  of	  their	  pregnancy,	  these	  women	  may	  be	  more	  likely	  to	  be	  using	  potentially	  teratogenic	  essential	  and	  non-­‐essential	  medications	  during	  critical	  phases	  of	  neural	  and	  cardiac	  development.	  	  
With	  only	  thirteen	  drugs	  FDA-­‐approved	  for	  use	  by	  pregnant	  women,	  pregnancy	  is	  in	  effect	  an	  off-­‐label	  condition	  (IOM,	  2010).	  This	  means	  that	  physicians	  work	  with	  little	  or	  no	  information	  regarding	  drug	  safety	  for	  pregnant	  women	  or	  their	  fetuses.	  As	  such,	  physicians	  have	  no	  choice	  but	  to	  write	  prescriptions	  and	  suggest	  therapies	  without	  being	  fully	  knowledgeable	  about	  the	  appropriate	  dosage	  or	  level	  of	  maternal-­‐fetal	  risk	  (Lyerly	  et	  al.,	  2009b).	  When	  uncertain	  about	  the	  existence	  or	  extent	  of	  drug	  or	  therapy-­‐induced	  malformations,	  physicians	  may	  recommend	  abortion	  of	  the	  fetus	  out	  of	  caution.	  	  
If	  a	  pregnant	  woman	  hadn’t	  originally	  intended	  to	  abort	  the	  fetus,	  but	  did	  so	  as	  a	  result	  of	  a	  misinformed,	  overly	  cautious	  recommendation	  from	  the	  physician,	  the	  medically	  unnecessary	  abortion	  would	  be	  a	  wrongful	  death	  (Lyerly	  et	  al.,	  2009b).	  The	  converse	  is	  also	  of	  concern	  such	  as	  when	  a	  malformed	  infant	  is	  born	  to	  a	  woman	  who	  would	  have	  chosen	  to	  abort	  the	  fetus	  had	  she	  known	  of	  its	  condition.	  The	  above-­‐mentioned	  realities	  underscore	  the	  importance	  of	  research	  that	  both	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identifies	  teratogens,	  and	  takes	  into	  consideration	  their	  varying	  effects	  during	  the	  course	  of	  pregnancy.	  
Lost	  therapeutic	  opportunities	  for	  pregnant	  women	  Insufficient	  maternal-­‐fetal	  research	  results	  in	  loss	  of	  therapeutic	  opportunities	  for	  pregnant	  women	  through	  various	  means,	  including:	  denial	  of	  benefits	  of	  participation	  in	  research,	  prescription	  of	  older,	  presumably	  safer	  medicines,	  and	  the	  disinclination	  of	  women	  to	  use	  or	  physicians	  to	  prescribe	  medications	  during	  pregnancy.	  
Denial	  of	  benefits	  of	  participation	  in	  research	  Clinical	  trials	  can	  in	  and	  of	  themselves	  function	  as	  a	  form	  of	  therapeutic	  intervention.	  Whether	  due	  to	  prohibitively	  expensive	  drug	  costs,	  drugs	  not	  yet	  available	  publicly	  or	  because	  the	  drug	  being	  tested	  is	  the	  patient’s	  last	  hope	  for	  effective	  treatment,	  participation	  in	  a	  clinical	  trial	  may	  be	  the	  only	  way	  for	  certain	  people	  to	  access	  necessary	  treatment	  (SWAP,	  2012).	  However,	  despite	  the	  Institute	  of	  Medicine’s	  recommendation	  that	  pregnant	  women	  be	  presumed	  eligible	  for	  participation,	  pregnancy	  remains	  grounds	  for	  near-­‐automatic	  exclusion	  from	  many	  clinical	  studies	  (Lyerly,	  2008).	  	  
Prescription	  of	  older	  medications	  As	  a	  result	  of	  exclusion	  from	  research	  and	  the	  resulting	  dearth	  of	  information	  about	  the	  safety	  of	  almost	  all	  drugs	  for	  use	  by	  pregnant	  women,	  physicians	  tend	  to	  prescribe	  older	  more	  established	  medications	  when	  possible.	  In	  the	  absence	  of	  more	  scientifically	  rigorous	  data,	  physicians	  and	  women	  can	  gain	  reassurance	  only	  by	  the	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absence	  of	  any	  reports	  of	  serious	  safety	  concerns	  during	  the	  drug’s	  relatively	  long	  history	  (Lyerly	  et	  al.,	  2009b).	  In	  addition	  to	  the	  potential	  health	  consequence	  of	  using	  inadequately	  tested	  drugs,	  regardless	  of	  how	  long	  ago	  they	  were	  inadequately	  tested,	  the	  hesitation	  to	  prescribe	  newer	  drugs	  denies	  pregnant	  women	  the	  opportunity	  to	  use	  potentially	  more	  effective	  and	  better	  tolerated	  drugs,	  in	  effect,	  hindering	  the	  ability	  of	  these	  women	  to	  benefit	  from	  biomedical	  innovation.	  
Disinclination	  to	  use	  or	  prescribe	  medication	  during	  pregnancy	  It	  is	  not	  uncommon	  for	  women	  to	  discontinue	  use	  or	  significantly	  reduce	  the	  dose	  of	  both	  essential	  and	  non-­‐essential	  medications	  they	  were	  taking	  once	  they	  learn	  they	  are	  pregnant	  (Lyerly	  et	  al.,	  2008).	  This	  can	  be	  in	  response	  to	  a	  misguided	  recommendation	  from	  a	  health	  care	  professional,	  or	  personal	  reluctance	  to	  expose	  the	  fetus	  to	  potential	  teratogens.	  This	  reluctance	  can	  lead	  to	  poor	  adherence	  to	  drug	  regimens	  prescribed	  by	  the	  physician	  to	  manage	  existing	  conditions	  or	  treat	  conditions	  that	  arise	  during	  or	  as	  a	  result	  of	  pregnancy	  (Lyerly	  et	  al.,	  2009b).	  
	   Prescribing	  lower	  doses	  of	  drugs	  to	  pregnant	  women	  is	  especially	  problematic	  in	  cases	  where	  pregnant	  women	  metabolize	  the	  drug	  much	  more	  rapidly	  than	  women	  who	  are	  not	  pregnant.	  Therefore,	  when	  a	  physician,	  unfamiliar	  with	  the	  pharmacokinetics	  of	  the	  specific	  drug,	  prescribes	  a	  lower	  dose	  to	  pregnant	  women,	  the	  dose	  may	  in	  effect	  have	  no	  therapeutic	  value. Furthermore,	  the	  under-­‐prescription	  or	  complete	  discontinuation	  of	  medication	  can	  compromise	  the	  health	  of	  the	  woman	  and	  the	  unborn	  fetus	  if	  they	  experience	  the	  harms	  of	  untreated	  illness	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(Lyerly	  et	  al.,	  2009b).	  Unfortunately,	  these	  consequences	  are	  too	  often	  ignored	  and	  under	  reported.	  
With	  regards	  to	  depression,	  the	  National	  Alliance	  on	  Mental	  Illness	  (NAMI)	  admonishes	  women	  to	  “if	  possible,	  stop	  using	  the	  drugs	  before	  trying	  to	  conceive	  [and]	  do	  everything	  possible	  to	  avoid	  medication	  in	  the	  first	  trimester	  of	  pregnancy”(NAMI,	  2012).	  What	  often	  receives	  less	  attention	  is	  that	  women	  who	  discontinue	  medication	  use	  have	  significantly	  higher	  rates	  of	  relapse	  of	  major	  depression	  (68	  percent)	  than	  those	  who	  continued	  medication	  (26	  percent).	  In	  fact,	  untreated	  depression	  is	  associated	  with	  premature	  birth,	  low	  birth	  weight,	  fetal	  growth	  restriction	  and	  postnatal	  complications,	  in	  addition	  to	  decreased	  social	  support,	  poor	  weight	  gain,	  and	  alcohol	  and	  drug	  use	  (Blazer	  et	  al.,	  2007;	  Altshuler	  et	  al.,	  2006).	  
	  The	  disinclination	  to	  prescribe	  or	  use	  drugs	  during	  pregnancy,	  has	  also	  been	  observed	  amongst	  pregnant	  women	  with	  asthma.	  Studies	  have	  found	  that	  many	  pregnant	  women	  who	  suffer	  from	  asthma	  stop	  using	  their	  medications	  due	  to	  misinformed	  fear	  of	  fetal	  harm.	  Discontinuing	  use	  of	  asthma	  medications	  is	  dangerous	  for	  both	  the	  pregnant	  woman	  and	  to	  the	  fetus.	  Poorly	  controlled	  asthma	  places	  the	  pregnant	  women	  at	  higher	  risk	  of	  hypertension,	  preeclampsia,	  and	  uterine	  hemorrhage,	  and	  the	  fetus	  at	  higher	  risk	  for	  intrauterine	  growth	  restriction,	  prematurity,	  and	  low	  perinatal	  weight.	  In	  contrast,	  women	  with	  well-­‐managed	  asthma	  have	  perinatal	  outcomes	  as	  good	  as	  comparable	  groups	  of	  women	  without	  asthma	  (Lyerly,	  2009;	  Tan	  et	  al.,	  2000).	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The	  disinclination	  of	  women	  to	  use,	  and	  physicians’	  reluctance	  to	  prescribe	  drugs	  and	  other	  therapeutics	  to	  pregnant	  women	  is	  a	  direct	  result	  of	  insufficient	  information	  about	  safety	  and	  dosage	  of	  medications	  for	  pregnant	  women.	  In	  addition,	  including	  lack	  of	  due	  consideration	  of	  the	  significant	  consequences	  of	  under-­‐treatment.	  
Chronic	  disease	  As	  women	  delay	  childbearing,	  and	  chronic	  diseases	  such	  as	  obesity,	  diabetes	  and	  heart	  disease	  continue	  to	  ravage	  the	  nation,	  pregnant	  women	  will	  require	  evidence-­‐based	  disease	  management	  (Bachman	  et	  al.,	  2008).	  According	  to	  the	  Centers	  for	  Disease	  Control	  and	  Prevention	  (CDC),	  obesity	  during	  pregnancy	  is	  now	  a	  common	  condition,	  affecting	  approximately	  20	  percent	  of	  pregnant	  women	  (CDC,	  2011).	  Obesity	  is	  associated	  with	  increased	  complications	  during	  pregnancy.	  A	  prospective	  multi-­‐center	  study	  of	  16,192	  women	  found	  that	  obese	  and	  morbidly	  obese	  women	  were	  2.5	  and	  3.2	  times	  (respectively)	  more	  likely	  to	  develop	  gestational	  diabetes	  than	  the	  control	  group	  of	  normal	  weight	  women	  (Catalano	  et	  al.,	  2006).	  The	  more	  health	  complications,	  the	  more	  likely	  the	  women	  were	  to	  be	  taking	  medications	  to	  manage	  their	  conditions.	  A	  study	  examining	  over	  13,000	  pregnancies	  within	  the	  data	  system	  of	  a	  large	  U.S.	  group-­‐practice	  health	  maintenance	  organization	  found	  that	  a	  higher	  than	  normal	  body	  mass	  index	  (BMI	  over	  25)	  was	  associated	  with	  significantly	  more	  medications	  dispensed	  from	  the	  outpatient	  pharmacy	  and	  increased	  length	  of	  hospital	  stay	  during	  delivery	  due	  to	  obesity	  related	  high-­‐risk	  conditions,	  including	  gestational	  hypertension,	  pre-­‐eclampsia	  and	  gestational	  diabetes	  (Bachman	  et	  al.,	  2008).	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Who	  is	  disproportionately	  burdened?	  
In	  the	  United	  States,	  one	  in	  five	  people	  live	  below	  100	  percent	  of	  the	  Federal	  Poverty	  Line	  (FPL).	  Based	  on	  the	  Census	  Bureau’s	  2011	  and	  2012	  Current	  Population	  Survey,	  despite	  the	  overall	  poverty	  rate	  of	  20	  percent,	  33	  percent	  of	  Hispanics	  and	  35	  percent	  of	  blacks	  live	  in	  poverty,	  as	  compared	  to	  a	  much	  smaller	  percentage	  of	  whites	  (13	  percent).	  Furthermore,	  a	  disparity	  exists	  across	  genders	  as	  well,	  with	  20	  percent	  of	  women	  and	  a	  lesser	  18	  percent	  of	  males	  living	  in	  poverty	  (KFF,	  2012).	  
The	  previous	  section	  highlighted	  some	  of	  the	  many	  ways	  in	  which	  the	  insufficient	  inclusion	  of	  pregnant	  women	  in	  medical	  research	  negatively	  affects	  women,	  children	  and	  their	  families.	  This	  section	  will	  outline	  select	  reasons	  why,	  and	  ways	  in	  which,	  low-­‐income	  populations	  of	  color	  are	  disproportionately	  burdened	  by	  this	  research	  deficiency.	  
Higher	  rates	  of	  chronic	  disease	  Women	  of	  color	  continue	  to	  have	  higher	  rates	  of	  chronic	  disease	  and	  mental	  illness	  than	  white	  women.	  In	  fact,	  for	  some	  conditions,	  despite	  new	  technologies	  and	  other	  recent	  advances,	  the	  disparities	  continue	  to	  grow	  (IOM,	  2010).	  For	  example,	  a	  ten-­‐year	  longitudinal	  population-­‐based	  study	  of	  racial	  disparity	  in	  hypertensive	  disorders	  in	  pregnancy	  found	  that	  although	  hospitalization	  rates	  for	  preeclampsia	  decreased	  over	  time	  for	  most	  groups,	  differences	  in	  rates	  between	  white	  and	  black	  women	  increased	  over	  the	  ten-­‐year	  period.	  In	  addition,	  black	  and	  Hispanic	  women	  were	  more	  likely	  than	  white	  women	  to	  have	  a	  form	  of	  diabetes	  and	  were	  at	  higher	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risk	  for	  preeclampsia.	  Preeclampsia	  rates	  were	  higher	  in	  these	  groups	  both	  with	  and	  without	  diabetes	  than	  in	  corresponding	  groups	  of	  white	  women	  (Bell	  et	  al.,	  2007).	  	  
	   In	  addition,	  although	  mental	  illness	  is	  a	  widespread	  problem	  that	  remains	  largely	  under-­‐diagnosed	  and	  untreated	  throughout	  the	  United	  States,	  studies	  have	  found	  both	  a	  higher	  prevalence	  of	  mental	  illness	  and	  higher	  rate	  of	  under-­‐treatment	  among	  minority	  populations	  (IOM,	  2010).	  For	  instance,	  the	  lifetime	  prevalence	  of	  any	  psychiatric	  disorder	  among	  American	  Indian	  women	  is	  41-­‐46	  percent	  higher	  than	  among	  the	  overall	  US	  population	  (Chapman	  et	  al.,	  2010).	  Evidence	  suggests	  that	  minority-­‐group	  members	  who	  live	  with	  depression	  are	  less	  likely	  to	  get	  treatment	  than	  white	  Americans.	  Furthermore,	  black	  women	  living	  with	  depression	  are	  less	  likely	  to	  receive	  high-­‐quality	  treatment,	  leading	  to	  longer,	  more	  severe	  bouts	  of	  depression	  than	  white	  Americans	  (IOM,	  2010).	  
Women	  with	  mental	  illness	  are	  at	  increased	  risk	  of	  negative	  outcomes	  for	  multiple	  reasons.	  First,	  they	  are	  more	  likely	  to	  require	  continuous	  use	  of	  medications	  throughout	  pregnancy	  (NAMI,	  2012).	  Second,	  they	  are	  more	  likely	  to	  mismanage	  their	  medication	  regimen,	  which	  may	  lead	  to	  the	  worsening	  of	  both	  their	  mental	  and	  physical	  state	  (Cramer	  et	  al.,	  1998).	  Third,	  as	  there	  are	  currently	  no	  psychotropic	  drugs	  FDA-­‐approved	  for	  use	  in	  pregnancy,	  concern	  for	  fetal	  safety	  may	  result	  in	  self-­‐imposed	  or	  doctor	  recommended	  discontinuation	  of	  medication	  use	  leading	  to	  risks	  associated	  with	  untreated	  psychiatric	  illness,	  (see	  section	  on	  “Discontinuing	  Use	  of	  Important	  Medications”)	  (NAMI,	  2012;	  Lyerly	  et	  al.,	  2007).	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   It	  follows	  that	  with	  higher	  rates	  of	  both	  chronic	  diseases	  and	  mental	  illness,	  that	  low-­‐income	  women	  of	  color	  would	  have	  a	  higher	  prevalence	  of	  comorbidity	  of	  mental	  illness	  with	  chronic	  diseases	  (Chapman	  et	  al.,	  2010).	  Comorbid	  conditions,	  such	  as	  depression	  and	  diabetes,	  are	  associated	  with	  use	  of	  a	  greater	  number	  of	  medications	  and	  with	  lower	  rates	  of	  medication	  adherence	  (Cramer	  et	  al.,	  1998).	  A	  review	  of	  research	  on	  medication	  compliance	  in	  psychiatric	  treatment	  found	  that	  patients	  receiving	  antidepressants	  took	  65	  percent	  of	  the	  recommended	  amount	  (range	  40-­‐90	  percent)	  (Cramer	  et	  al.,	  1998).	  Both	  the	  increased	  number	  of	  medications	  and	  poor	  medication	  compliance	  increase	  a	  pregnant	  woman’s	  risk	  for	  negative	  health	  outcomes.	  	  
Less	  likely	  to	  use	  preventive	  services	  In	  the	  United	  States,	  over	  40	  percent	  of	  Americans	  have	  employer-­‐based	  health	  insurance;	  however,	  low-­‐income	  Americans	  are	  less	  likely	  to	  work	  in	  establishments	  that	  provide	  health	  insurance	  for	  their	  employees.	  Historically,	  the	  high	  cost	  of	  health	  insurance	  has	  resulted	  in	  low	  rates	  of	  comprehensive	  coverage	  in	  this	  population	  (KFF,	  2009).	  Although	  public	  assistance	  programs	  are	  available	  for	  certain	  segments	  of	  the	  population	  (based	  on	  categorical,	  income	  and	  asset	  tests),	  unmet	  need	  is	  still	  high	  and	  disparities	  remain.	  Data	  from	  2010	  showed	  that	  American	  Indians	  are	  16.1	  percent	  and	  Hispanics	  18.3	  percent	  more	  likely	  to	  be	  uninsured	  than	  non-­‐Hispanic	  whites,	  and	  non-­‐citizens	  are	  almost	  three	  times	  as	  likely	  to	  be	  uninsured	  than	  native	  U.S.	  citizens	  (KFF,	  2011).	  Lack	  of	  health	  insurance	  is	  associated	  with	  reduced	  access	  and	  use	  of	  preventive	  services,	  including	  Pap	  tests,	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blood	  pressure	  checks,	  mammograms,	  and	  cholesterol	  tests	  (Sambarmoorthi	  et	  al.,	  2003).	  	  
Timely	  use	  of	  evidence-­‐based	  preventive	  services	  is	  associated	  with	  better	  health	  outcomes.	  For	  instance,	  routine	  cholesterol	  tests	  may	  result	  in	  the	  early	  diagnosis	  of	  high	  cholesterol.	  The	  early	  diagnosis	  allows	  for	  the	  health	  care	  provider	  to	  counsel	  the	  patient	  on	  diet	  and	  lifestyle	  factors	  that	  can	  be	  altered	  to	  manage	  their	  cholesterol.	  Preventing	  the	  progression	  of	  disease	  often	  helps	  lessen	  the	  number	  of	  medications	  required	  to	  manage	  or	  treat	  a	  more	  advanced	  stage	  of	  the	  disease.	  Therefore,	  a	  population,	  that	  has	  restricted	  access	  to	  preventive	  services,	  including	  disease	  management,	  is	  at	  increased	  risk	  for	  more	  serious	  health	  complications,	  resulting	  in	  an	  increased	  reliance	  on	  prescription	  medications.	  Because	  of	  the	  inadequate	  research	  on	  medications	  in	  pregnancy,	  this	  is	  especially	  problematic	  for	  pregnant	  women.	  	  
	   The	  Patient	  Protection	  and	  Affordable	  Care	  Act	  (2010)	  expands	  access	  to	  health	  insurance	  via	  Medicaid	  expansion	  and	  insurance	  subsidies.	  In	  states	  that	  choose	  to	  expand	  Medicaid,	  childless,	  non-­‐disabled	  adults	  with	  incomes	  no	  greater	  than	  138	  percent	  FPL	  will	  become	  newly	  eligible	  for	  Medicaid	  in	  2014.	  Currently	  pregnant	  women	  with	  incomes	  below	  185	  percent	  FPL	  are	  eligible	  for	  Medicaid;	  after	  2014,	  states	  that	  chose	  to	  expand	  Medicaid	  are	  only	  required	  to	  provide	  coverage	  for	  pregnant	  women	  with	  incomes	  below	  138	  percent	  FPL,	  but	  will	  still	  have	  the	  option	  to	  extend	  coverage	  back	  up	  to	  185	  percent	  FPL	  (PPACA	  Sec.	  2001	  and	  2002,	  2010).	  In	  addition,	  refundable	  advanceable	  premium	  credits	  will	  be	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available	  to	  individuals	  with	  incomes	  between	  100	  and	  400	  percent	  FPL	  who	  are	  purchasing	  insurance	  in	  the	  Health	  Benefit	  Exchange	  (KFF,	  2009).	  Similarly,	  subsidies	  will	  be	  available	  for	  employers	  with	  25	  or	  fewer	  employees,	  and	  larger	  employees	  will	  be	  required	  to	  offer	  insurance	  or	  pay	  a	  penalty.	  Although	  there	  are	  some	  exemptions,	  the	  ACA	  also	  introduces	  an	  individual	  mandate	  that	  requires	  citizens	  and	  legal	  immigrants	  to	  be	  enrolled	  in	  qualified	  health	  insurance	  plan	  or	  pay	  a	  penalty	  (PPACA	  Sec.	  1501(d)(2)-­‐(4)-­‐(e),	  2010).	  	   Furthermore,	  all	  qualified	  health	  plans	  (except	  those	  with	  grandfathered	  status)	  will	  be	  required	  to	  cover	  an	  essential	  benefits	  package	  which	  includes	  amongst	  other	  things,	  various	  preventive	  and	  wellness	  services.	  Clinical	  preventive	  services	  recommended	  with	  an	  A	  or	  B	  recommendation	  by	  the	  US	  Preventive	  Services	  Task	  Force	  or	  immunizations	  recommended	  by	  the	  Advisory	  Committee	  for	  Immunization	  Practices	  must	  be	  covered	  by	  all	  plans	  (except	  grandfathered)	  with	  no	  cost	  sharing	  (PPACA	  Sec.	  1001	  10406,	  2010).	  	  The	  PPACA	  does	  much	  to	  expand	  health	  insurance	  coverage;	  however,	  lack	  of	  insurance	  is	  only	  one	  of	  many	  factors	  contributing	  to	  lower	  use	  of	  preventive	  services	  by	  low-­‐income	  women	  of	  color.	  Other	  barriers	  include	  access	  and	  transportation	  limitations,	  distrust	  of	  the	  medical	  system	  and	  linguistic	  or	  cultural	  barriers.	  Without	  addressing	  these	  and	  other	  barriers,	  the	  PPACA	  related	  increase	  in	  preventive	  service	  use	  by	  low-­‐income	  populations	  of	  color	  is	  likely	  to	  be	  limited	  (Sambarmoorthi	  et	  al.,	  2003).	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Higher	  rates	  of	  unintended	  pregnancy	  Unintended	  pregnancies	  are	  defined	  as	  pregnancies	  that	  are	  either	  mistimed	  or	  unwanted	  (Guttmacher	  Institute,	  2012).	  	  Although	  it	  is	  true	  that	  women	  of	  all	  ages	  and	  backgrounds	  may	  have	  unintended	  pregnancies,	  a	  study	  conducted	  by	  the	  Guttmacher	  Institute	  found	  that	  certain	  subgroups,	  such	  as	  women	  who	  are	  18-­‐24	  years	  old,	  poor,	  or	  cohabiting	  had	  unintended	  pregnancy	  rates	  that	  were	  two	  or	  three	  times	  the	  national	  rate	  (Finer	  et	  al.,	  2011).	  Upon	  graphing	  the	  unintended	  pregnancy	  rates	  for	  women	  aged	  15-­‐44	  from	  1981-­‐2006,	  it	  becomes	  clear	  that	  unintended	  pregnancy	  is	  becoming	  increasingly	  concentrated	  among	  low-­‐income	  women	  (Guttmacher	  Institute,	  2012).	  Although	  the	  US	  Department	  of	  Health	  and	  Human	  Services	  has	  identified	  reducing	  unintended	  pregnancies	  as	  an	  ongoing	  priority,	  the	  national	  rate	  has	  not	  been	  estimated	  since	  2001	  (Finer	  et	  al.,	  2011).	  	  
Births	  resulting	  from	  unintended	  or	  closely-­‐spaced	  pregnancies	  are	  associated	  with	  adverse	  health	  outcomes	  for	  both	  the	  mother	  and	  child;	  some	  such	  outcomes	  include:	  delayed	  initiation	  of	  prenatal	  care,	  premature	  birth,	  and	  negative	  mental	  and	  health	  impact	  for	  children	  (Guttmacher	  Institute,	  2012).	  And	  as	  mentioned	  previously,	  a	  woman	  experiencing	  an	  unplanned	  pregnancy	  is	  less	  likely	  to	  realize	  she	  is	  pregnant	  during	  the	  earliest	  and	  most	  critical	  stages	  of	  embryonic	  development.	  This	  means	  she	  is	  more	  likely	  to	  be	  using	  medications,	  including	  non-­‐essential	  teratogens,	  while	  the	  fetus’	  central	  nervous	  system	  and	  heart	  are	  most	  susceptible	  to	  disruption	  in	  development	  and	  consequent	  congenital	  malformations	  (Lee	  et	  al.,	  2006).	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Less	  likely	  to	  be	  a	  research	  subject	  For	  reasons	  ranging	  from	  historical	  trauma	  and	  distrust	  to	  unsuitable	  study	  designs	  and	  scheduling	  conflicts,	  women	  of	  color	  remain	  underrepresented	  in	  clinical	  studies	  and	  trials	  (IOM,	  2010).	  The	  insufficient	  inclusion	  of	  minority	  women,	  much	  like	  the	  insufficient	  inclusion	  of	  pregnant	  women	  in	  general,	  has	  myriad	  consequences.	  Perhaps	  the	  most	  notable	  consequence	  is	  that	  without	  a	  study	  population	  that	  represents	  the	  diversity	  of	  the	  populations	  to	  which	  the	  results	  will	  be	  applied,	  generalizability	  is	  diminished.	  Without	  sufficient	  inclusion,	  neither	  minority	  women	  nor	  their	  physicians	  can	  be	  confident	  that	  the	  recommendations	  that	  result	  from	  these	  studies	  are	  entirely	  applicable.	  As	  a	  result,	  there	  is	  a	  lower	  overall	  quality	  of	  care	  for	  these	  populations	  (Killien	  et	  al.,	  2000).	  
More	  financially	  constrained	  For	  an	  individual	  or	  a	  family,	  having	  limited	  financial	  resources	  may	  in	  many	  ways	  worsen	  the	  consequences	  of	  insufficient	  inclusion	  of	  pregnant	  women	  in	  research.	  One	  such	  way	  is	  in	  the	  increased	  financial	  burden	  of	  caring	  for	  a	  child	  with	  disabilities,	  in	  this	  case	  disabilities	  that	  resulted	  from	  intrauterine	  exposure	  to	  a	  teratogen.	  Children	  with	  special	  health	  care	  needs	  (CSHCN)	  often	  require	  health	  and	  related	  services	  of	  a	  type	  or	  amount	  beyond	  that	  required	  by	  children	  generally	  	  (Kuhlthau	  et	  al.,	  2005).	  Results	  from	  the	  2005-­‐2006	  National	  Survey	  of	  Children	  with	  Special	  Health	  Care	  needs	  indicated	  that	  parents	  of	  18	  percent	  of	  CSHCN	  report	  that	  their	  child’s	  financial	  condition	  has	  caused	  financial	  problems	  for	  the	  family.	  The	  financial	  burden	  was	  greatest	  for	  the	  families	  of	  CSHCN	  who	  are	  uninsured.	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Nearly	  42	  percent	  of	  uninsured	  CSHCN	  live	  in	  families	  that	  reported	  a	  financial	  problem,	  compared	  to	  20	  percent	  of	  those	  with	  only	  public	  coverage	  and	  15	  percent	  of	  those	  with	  private	  insurance.	  These	  problems	  are	  exacerbated	  if	  parents	  must	  stop	  working	  or	  cut	  their	  hours	  to	  care	  for	  their	  children,	  as	  24	  percent	  reported	  that	  they	  did	  (HRSA,	  2006).	  	  
However,	  with	  the	  passing	  of	  PPACA	  families	  of	  CSHCN	  may	  experience	  some	  lessening	  of	  care-­‐related	  financial	  burden.	  A	  report	  by	  the	  Health	  &	  Disability	  Working	  Group	  at	  the	  Boston	  University	  School	  of	  Public	  Health	  outlines	  various	  provisions	  in	  the	  law	  and	  potential	  implications	  for	  CSHCN	  and	  their	  families.	  Some	  provisions	  of	  note	  include:	  coverage	  of	  pre-­‐existing	  conditions	  and	  extension	  of	  coverage	  for	  young	  adults	  on	  their	  parent’s	  policy	  to	  age	  26,	  eligibility	  simplification,	  limits	  on	  out-­‐of-­‐pocket	  expenditures	  and	  essential	  benefit	  coverage	  (Health	  and	  Disability	  Working	  Group,	  2011).	  	  
Call	  for	  action	  
As	  outlined	  in	  this	  paper,	  there	  are	  many	  reasons	  why,	  and	  ways	  in	  which,	  the	  insufficient	  inclusion	  of	  pregnant	  women	  in	  biomedical	  research	  is	  problematic	  for	  pregnant	  women	  and	  their	  fetuses.	  Furthermore,	  the	  unequal	  distribution	  of	  consequences	  reinforces	  the	  status	  quo	  by	  disproportionately	  burdening	  individuals	  already	  socioeconomically	  and	  systematically	  disadvantaged.	  These	  consequences	  affect	  both	  women	  and	  their	  potential	  offspring	  and	  have	  intergenerational,	  long-­‐lasting	  and	  self-­‐perpetuating	  effects.	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Ethicists	  have	  produced	  considerable	  literature	  regarding	  the	  moral	  implications	  of	  health	  inequalities	  such	  as	  those	  discussed	  in	  this	  paper	  (Mastroianni	  et	  al.,	  1994;	  Beauchamp	  et	  al.,	  2001;	  Faden	  et	  al.,	  2006).	  Bioethicists,	  including	  feminist	  theorists,	  have	  employed	  various	  justice	  arguments	  to	  establish	  that	  these	  disparities	  are	  unjust	  and	  require	  redress.	  	  While	  the	  full	  breadth	  and	  details	  of	  these	  arguments	  is	  beyond	  the	  scope	  of	  this	  manuscript,	  I	  offer	  a	  brief	  review	  of	  major	  arguments	  below.	  	  
	  
Ethical	  Arguments	  In	  their	  book	  Principles	  of	  Biomedical	  Ethics	  (2001),	  bioethicists	  Beauchamp	  and	  Childress	  outline	  four	  principles	  of	  biomedical	  ethics.	  This	  framework	  offers	  broad	  consideration	  of	  both	  medical	  ethics	  issues	  generally	  and	  clinically,	  and	  is	  amongst	  the	  most	  widely	  used	  in	  the	  field.	  The	  four	  principles	  include:	  
1. Respect	  for	  autonomy	  –	  respecting	  the	  decision-­‐	  making	  capacities	  of	  autonomous	  persons;	  enabling	  individuals	  to	  make	  reasoned	  informed	  choices.	  
2. Beneficence	  –	  the	  balancing	  of	  benefits	  of	  treatment	  against	  the	  risks	  and	  costs;	  the	  healthcare	  professional	  should	  act	  in	  such	  a	  way	  that	  benefits	  the	  patient	  
3. Nonmaleficence	  –	  the	  healthcare	  professional	  should	  not	  harm	  the	  patient.	  If	  some	  harm	  is	  unavoidable,	  it	  should	  not	  be	  disproportionate	  to	  the	  benefits	  of	  treatment	  
4. Justice	  –	  distributing	  benefits,	  risks	  and	  costs	  fairly;	  the	  notion	  that	  patients	  in	  similar	  positions	  should	  be	  treated	  in	  a	  similar	  manner.	  While	  the	  under-­‐representation	  of	  pregnant	  women	  and	  the	  disparate	  impact	  with	  regard	  to	  race	  and	  socioeconomic	  status	  is	  problematic	  in	  terms	  of	  all	  four	  principles,	  it	  raises	  particular	  concerns	  with	  regards	  to	  justice.	  Beauchamp	  and	  Childress	  argue	  that	  the	  benefits	  and	  burdens	  of	  research	  should	  be	  distributed	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equitably.	  In	  particular,	  they	  propose	  a	  society	  that	  recognizes	  “an	  enforceable	  right	  to	  a	  decent	  minimum	  of	  health	  care	  within	  a	  framework	  of	  allocation	  that	  incorporates	  both	  utilitarian	  and	  egalitarian	  standards”	  (2001,	  p.	  272).	  
Feminist	  ethicists,	  such	  as	  Young	  and	  DeBruin,	  go	  further;	  arguing	  that	  the	  distributive	  paradigm	  of	  justice	  fails	  to	  capture	  all	  there	  is	  to	  justice.	  Young	  argues:	  (1)	  not	  all	  concerns	  of	  justice	  are	  maters	  of	  distribution	  of	  benefits	  and	  burdens,	  (2)	  
oppression	  qualifies	  as	  a	  concern	  of	  justice,	  (3)	  an	  exclusive	  focus	  on	  individuals	  fails	  to	  capture	  important	  aspects	  of	  justice	  as	  people	  are	  oppressed	  not	  as	  individuals	  but	  as	  members	  of	  groups	  (DeBruin,	  1994).	  	  	  
DeBruin	  (1994)	  holds	  that	  oppression:	  makes	  women	  invisible,	  makes	  them	  appear	  deviant	  and	  imposes	  gender	  norms	  on	  women,	  subordinating	  them	  to	  men.	  She	  argues	  that	  justice	  requires	  the	  elimination	  of	  oppression,	  and	  that	  our	  practices	  concerning	  the	  inclusion	  of	  women	  in	  studies	  are	  a	  both	  result	  and	  a	  cause	  of	  oppression.	  	  
Ethicists	  Faden	  and	  Powers	  (2006)	  also	  stress	  that	  justice	  is	  concerned	  with	  more	  than	  just	  distributive	  principles,	  instead	  maintaining	  that	  it	  is	  concerned	  with	  six	  essential	  dimensions	  of	  well	  being:	  health,	  personal	  security,	  reasoning,	  respect	  attachment	  and	  self-­‐determination.	  In	  their	  book	  Social	  Justice	  (2006),	  they	  write:	  
We	  contend	  that	  each	  of	  these	  dimensions	  is	  an	  essential	  feature	  of	  well-­‐being	  such	  
that	  a	  life	  substantially	  lacking	  in	  any	  one	  is	  a	  life	  seriously	  deficient	  in	  what	  is	  
reasonable	  for	  anyone	  to	  want,	  whatever	  else	  they	  want	  (p.6).	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Central	  to	  their	  argument	  is	  a	  sufficiency	  theory	  of	  justice,	  a	  form	  of	  egalitarianism	  in	  a	  broad	  sense.	  They	  view	  the	  central	  aspiration	  of	  justice	  to	  be	  sufficiency	  of	  well-­‐	  being,	  not	  equality	  of	  well-­‐being.	  Therefore	  any	  inequity	  in	  the	  social	  determinants	  that	  contributes	  to	  persons	  falling	  below	  a	  level	  of	  sufficiency	  will	  be	  of	  high	  importance.	  	  Faden	  and	  Powers	  argue	  for	  a	  unified	  theory	  of	  social	  determinants	  and	  well-­‐being,	  as	  they	  recognize	  the	  densely	  woven,	  systematic	  patterns	  of	  disadvantage.	  By	  claiming	  that	  social	  justice	  is	  the	  foundational	  moral	  justification	  of	  the	  institution	  of	  public	  health,	  they	  call	  public	  health	  to	  action	  (2006).	  Ultimately,	  the	  various	  theories	  of	  justice	  indicate	  that	  the	  disparities	  raised	  by	  the	  current	  approach	  to	  research	  with	  pregnant	  women	  should	  be	  redressed	  as	  a	  matter	  of	  ethically	  responsible	  public	  health	  and	  policy.	  	  
Other	  Arguments	  In	  addition	  to	  the	  ethical	  concerns	  regarding	  fairness,	  the	  health	  disparities	  perpetuated	  by	  these	  injustices	  have	  impacts	  on	  a	  societal	  level.	  The	  American	  Public	  Health	  Association	  has	  argued	  that	  health	  disparities	  have	  negative	  economic	  and	  non-­‐economic	  consequences	  for	  all	  Americans,	  regardless	  of	  race	  or	  ethnicity	  (Suthers,	  2008).	  According	  to	  Healthy	  People	  2010:	  
The	  health	  of	  the	  individual	  is	  almost	  inseparable	  from	  the	  health	  of	  the	  larger	  
community	  …	  the	  health	  of	  the	  larger	  community	  and	  …	  the	  health	  of	  every	  community	  
and	  every	  State	  and	  territory	  determines	  the	  overall	  health	  status	  of	  the	  Nation	  (HHS,	  2010).	  With	  such	  an	  intermingled	  fate,	  it	  is	  in	  the	  interest	  of	  society	  to	  work	  towards	  the	  elimination	  of	  health	  disparities.	  The	  following	  section	  includes	  specific	  recommendations	  for	  action.	  
	   27	  
Recommendations	  for	  action	  
The	  Institute	  of	  Medicine’s	  Committee	  on	  Women’s	  Health	  Research	  and	  the	  Second	  Wave	  Initiative	  have	  developed	  numerous	  recommendations	  for	  increasing	  the	  responsible	  inclusion	  of	  pregnant	  women	  into	  biomedical	  research.	  Many	  of	  the	  recommendations	  are	  inspired	  by	  successes	  in	  the	  pediatric	  arena.	  Although	  children,	  like	  pregnant	  women,	  are	  deemed	  a	  vulnerable	  population,	  children	  are	  no	  longer	  considered	  “therapeutic	  orphans”	  due	  to	  various	  pieces	  of	  legislation	  that	  have	  supported	  their	  inclusion	  in	  research	  during	  the	  last	  fifteen	  years	  (Greenwood,	  2011).	  Recommendations	  for	  addressing	  pertinent	  legal	  and	  non-­‐legal	  challenges	  to	  adequate	  inclusion	  of	  pregnant	  women	  are	  discussed	  below.	  
Develop	  more	  nuanced	  regulations	  The	  1993	  NIH	  Revitalization	  Act	  requires	  both	  the	  inclusion	  of	  women	  in	  all	  clinical	  research,	  and	  the	  analysis	  of	  results	  by	  sex	  for	  phase	  III	  (effectiveness	  confirming)	  clinical	  trials;	  however,	  despite	  this	  legislation,	  pregnant	  women	  remain	  largely	  excluded	  (IOM,	  2010).	  Although	  it	  is	  admittedly	  difficult	  to	  strike	  an	  appropriate	  balance	  between	  fetal	  protections,	  permissible	  trade-­‐offs	  in	  maternal	  and	  fetal	  risks,	  and	  sound	  scientific	  methodology,	  answering	  certain	  research	  questions	  requires	  the	  imposition	  of	  at	  least	  some	  risk	  to	  the	  fetus.	  Current	  regulations	  employ	  either	  highly	  restrictive	  bright-­‐line	  criteria	  or	  ill-­‐defined	  standards	  that	  give	  little	  guidance	  to	  institutional	  review	  boards	  (Little	  et	  al.,	  2011).	  A	  more	  nuanced	  framework	  should	  be	  developed	  with	  the	  consultation	  of	  a	  diverse	  group	  of	  scientists,	  women’s	  advocates	  and	  ethicists	  knowledgeable	  about	  the	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distinctive	  context	  of	  pregnancy.	  The	  framework	  should	  consider	  indexing	  levels	  of	  acceptable	  fetal	  risk	  to	  the	  severity	  of	  need	  in	  pregnant	  women	  for	  the	  proposed	  therapeutic	  (Second	  Wave	  Initiative,	  2012).	  	  
Pursue	  more	  innovative	  study	  designs	  
	   In	  addition	  to	  developing	  more	  nuanced	  research	  regulations,	  there	  is	  a	  need	  for	  innovation	  with	  regards	  to	  study	  designs.	  The	  IOM	  recommends	  that	  NIH	  and	  other	  federal	  agencies	  and	  relevant	  professional	  organizations	  convene	  conferences	  or	  meetings	  to	  develop	  study	  methods	  and	  statistical	  techniques	  that	  will	  facilitate	  analysis	  of	  data	  on	  subgroups	  without	  substantially	  increasing	  the	  overall	  size	  of	  a	  study	  population.	  Furthermore,	  they	  argue	  that	  the	  Department	  of	  Health	  and	  Human	  Services	  Office	  of	  the	  National	  Coordinator	  for	  Health	  Information	  Technology	  should	  support	  the	  development	  and	  application	  of	  mechanisms	  for	  pooling	  patient	  and	  subject	  data	  to	  answer	  research	  questions	  that	  are	  not	  definitively	  answered	  by	  single	  studies	  (IOM,	  2010).	  
	  	   Along	  with	  the	  need	  for	  innovative	  approaches	  to	  future	  studies,	  both	  the	  IOM	  (2010)	  and	  the	  Second	  Wave	  Initiative	  (2012)	  recommend	  that	  efforts	  be	  made	  to	  procure	  efficacy	  and	  safety	  data	  from	  pharmacokinetic	  studies	  of	  women	  already	  taking	  medication	  during	  pregnancy,	  cohort	  registries,	  and	  case-­‐control	  surveillance	  studies	  that	  involve	  no	  additional	  risk	  to	  the	  fetus.	  One	  such	  example	  is	  the	  National	  Children’s	  Study	  (NCS),	  which	  the	  Second	  Wave	  Initiative	  has	  identified	  to	  be	  a	  golden	  opportunity	  for	  advancing	  the	  health	  of	  pregnant	  women	  (Lyerly	  et	  al.,	  2009a).	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   The	  National	  Children’s	  Study	  is	  the	  largest-­‐ever	  study	  of	  children’s	  health.	  With	  a	  $3	  billion	  investment	  by	  the	  federal	  government,	  the	  study	  aims	  to	  examine	  the	  effects	  of	  the	  environment	  on	  children	  from	  the	  fetal	  period	  to	  21	  years	  of	  age.	  Consequently,	  children	  in	  the	  study	  are	  selected	  through	  a	  sample	  of	  pregnant	  women,	  presenting	  a	  rare	  and	  valuable	  opportunity	  to	  study	  the	  health	  of	  women	  during	  and	  after	  pregnancy,	  in	  addition	  to	  the	  health	  of	  their	  children	  (Lyerly	  et	  al.,	  2009a).	  By	  expanding	  the	  scope	  of	  the	  study	  to	  include	  more	  complete	  information	  about	  the	  health	  status	  of	  pregnant	  women	  and	  pregnancy	  outcomes,	  as	  predictors	  for	  not	  only	  fetal	  and	  pediatric	  outcomes,	  but	  for	  women’s	  health	  itself,	  NCS	  could	  produce	  a	  wealth	  of	  much	  needed	  data,	  and	  would	  do	  so	  without	  introducing	  additional	  risk	  to	  pregnant	  women	  or	  their	  fetuses.	  
	   In	  order	  to	  accommodate	  innovative	  study	  designs	  that	  recruit	  pregnant	  women,	  IRB	  members	  should	  familiarize	  themselves	  with	  such	  designs,	  and	  think	  creatively	  about	  how	  to	  minimize	  and	  justify	  risks	  to	  mothers	  and	  fetuses	  by	  considering	  the	  potential	  gain	  to	  evidence-­‐based	  treatment	  guidelines	  for	  use	  of	  medication	  during	  pregnancy	  (SWAP,	  2012).	  
Alter	  labeling	  to	  more	  effectively	  communicate	  evidence-­‐based	  guidance	  to	  
medication	  use	  in	  pregnancy	  	  	   Since	  1975,	  the	  FDA	  has	  required	  drug	  labeling	  to	  include	  a	  subsection	  on	  a	  drug’s	  ability	  to	  cause	  birth	  defects	  and	  other	  effects	  on	  reproduction	  and	  pregnancy.	  Furthermore,	  drugs	  must	  be	  classified	  as	  belonging	  to	  either	  Category	  A,	  B,	  C,	  D	  or	  X	  (see	  Table	  2)	  based	  in	  the	  extent	  to	  which	  the	  drug	  has	  been	  shown	  to	  be	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safe	  in	  clinical	  trials	  including	  pregnant	  women	  or	  animals.	  In	  1997,	  a	  public	  hearing	  revealed	  that	  the	  category	  system	  was	  confusing	  and	  led	  to	  oversimplification	  as	  many	  assumed	  that	  the	  letters	  implied	  a	  gradation	  of	  risk	  (Meadows,	  2001).	  	  
Table	  2.	  Categories	  for	  drug	  use	  in	  pregnancy	  (Meadows,	  2001).	  Category	   Description	  A	   Adequate	  and	  well-­‐controlled	  studies	  have	  been	  conducted	  in	  pregnant	  women	  and	  shown	  no	  risk	  to	  the	  fetus	  in	  the	  first	  trimester	  of	  pregnancy	  and	  there	  is	  no	  evidence	  of	  risk	  in	  later	  trimesters.	  
B	   Animal	  studies	  have	  been	  conducted	  and	  shown	  no	  risk	  but	  there	  are	  no	  adequate	  and	  well-­‐controlled	  studies	  in	  pregnant	  women,	  or	  if	  animal	  studies	  have	  shown	  a	  risk	  but	  adequate	  and	  well-­‐controlled	  studies	  in	  pregnant	  women	  have	  been	  conducted	  and	  did	  not	  show	  a	  risk.	  
C	   Covers	  drugs	  the	  risks	  of	  which	  have	  not	  been	  studied	  in	  pregnant	  animals	  or	  pregnant	  women;	  it	  also	  covers	  drugs	  that	  animal	  studies	  have	  shown	  pose	  a	  risk	  to	  the	  fetus	  and	  that	  have	  not	  been	  studied	  in	  pregnant	  women.	  
D	   Used	  if	  there	  is	  positive	  evidence	  of	  human	  fetal	  risk	  based	  on	  adverse	  reaction	  data	  from	  investigational	  or	  marketing	  experience	  or	  studies	  in	  humans,	  but	  the	  potential	  benefits	  from	  the	  use	  of	  the	  drug	  in	  the	  pregnant	  women	  may	  be	  acceptable	  despite	  its	  potential	  risks.	  X	   Drugs	  for	  which	  the	  risk	  of	  use	  in	  pregnant	  women	  clearly	  outweighs	  any	  possible	  benefit.	  	  
In	  response	  to	  this	  hearing,	  the	  FDA	  began	  developing	  a	  new	  regulation	  that	  would	  revamp	  the	  pregnancy	  labeling	  system;	  over	  a	  decade	  later	  a	  rule	  proposal	  was	  published,	  and	  in	  2012	  the	  rule	  still	  had	  not	  gone	  into	  effect.	  The	  major	  changes	  being	  proposed	  by	  the	  FDA	  would	  provide	  available	  scientific	  information	  in	  a	  clear	  an	  accessible	  format	  for	  use	  by	  pregnant	  and	  nursing	  women.	  The	  new	  format	  would	  include	  a	  risk	  summary	  and	  information	  about	  the	  on	  available	  data	  on	  use	  of	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the	  drug	  during	  pregnancy	  and	  while	  breastfeeding	  (FDA,	  2011).	  	  This	  proposition,	  although	  slow	  to	  be	  realized,	  must	  be	  highlighted	  and	  supported.	  
Government	  intervention	  No	  matter	  the	  cause,	  the	  underproduction	  of	  maternal-­‐fetal	  medication	  research	  by	  the	  private	  market	  warrants	  government	  intervention.	  Ideas	  for	  intervention	  include:	  (1)	  Eliminating	  the	  liability	  barrier	  facing	  pharmaceutical	  companies,	  (2)	  Incentivizing	  manufacturers	  by	  offering	  an	  extended	  period	  of	  exclusivity,	  (3)	  Government	  funded	  or	  mandated	  research.	  The	  following	  section	  will	  elaborate	  on	  all	  three	  propositions,	  before	  concluding	  that	  government-­‐funded	  or	  mandated	  research	  is	  likely	  to	  be	  the	  most	  efficient	  and	  effective.	  
Eliminating	  the	  liability	  barrier	  facing	  pharmaceutical	  companies	  The	  National	  Vaccine	  Injury	  Compensation	  Program	  (VICP),	  established	  in	  1986,	  relieves	  companies	  from	  the	  unpredictability	  of	  tort	  reliability	  by	  compensating	  them	  in	  an	  alternate	  system.	  Claimants	  are	  entitled	  to	  a	  presumption	  of	  causation	  if	  they	  show	  (via	  petition)	  that	  they	  were	  administered	  a	  vaccine	  listed	  on	  the	  VICP	  Vaccine	  Injury	  Table	  and	  sustained	  an	  injury	  within	  a	  certain	  time	  period.	  Should	  a	  claimant	  choose	  to	  decline	  compensation	  proffered,	  they	  may	  sue	  the	  vaccine’s	  administrator	  or	  manufacturer	  directly.	  Once	  in	  court	  vaccine	  manufacturers	  are	  protected	  from	  various	  liabilities	  (HHS,	  2012).	  	  
Childhood	  vaccines	  are	  particularly	  appropriate	  for	  an	  alternative	  no-­‐fault	  compensation	  system	  as	  it	  is	  in	  the	  interest	  of	  the	  public’s	  health	  for	  all	  or	  almost	  all	  children	  to	  be	  vaccinated	  to	  achieve	  “herd-­‐immunity”.	  Because	  such	  a	  large	  number	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of	  children	  are	  vaccinated,	  the	  small	  risk	  of	  harm	  that	  a	  vaccine	  holds	  has	  real	  and	  predictable	  population	  level	  consequences.	  Without	  a	  no-­‐fault	  compensation	  system	  costs	  of	  liability	  would	  be	  potentially	  crippling	  for	  manufacturers.	  Maternal-­‐fetal	  medication	  risk	  is	  distinguishable	  from	  mass-­‐inoculation	  in	  various	  important	  ways.	  For	  one,	  the	  smaller	  numbers	  of	  individuals	  involved	  suggest	  that	  the	  resultant	  liability	  would	  not	  be	  so	  crippling	  that	  a	  no-­‐fault	  compensation	  system	  would	  be	  justified.	  Perhaps	  most	  importantly,	  there	  is	  little	  evidence	  to	  suggest	  that	  adoption	  of	  an	  alternative	  system	  would	  motivate	  manufacturers	  to	  implement	  robust	  maternal-­‐fetal	  research	  agendas	  (Greenwood,	  2011)	  
Incentivizing	  manufacturers	  	  In	  response	  to	  the	  information	  gap	  in	  drug	  efficacy	  and	  safety	  for	  children,	  Congress	  responded	  by	  enacting	  a	  pediatric	  exclusivity	  provision	  in	  1997	  (later	  reenacted	  as	  part	  of	  the	  Best	  Pharmaceuticals	  for	  Children	  Act	  (BPCA)).	  The	  provision	  provides	  that	  when	  a	  drug	  is	  still	  under	  patent	  or	  other	  exclusivity	  term,	  a	  company	  may	  be	  awarded	  an	  additional	  six	  months	  of	  exclusivity	  for	  all	  the	  drug’s	  formulation	  and	  indications,	  in	  exchange	  for	  completing	  FDA-­‐requested	  safety,	  efficacy	  and	  pharmacokinetic	  pediatric	  studies	  (Greenwood,	  2011).	  Though	  popular	  with	  the	  innovator	  drug	  industry,	  the	  BPCA	  pediatric	  exclusivity	  has	  many	  critics.	  Of	  these	  critics,	  some	  question	  its	  effectiveness,	  and	  many	  argue	  that	  it	  is	  grossly	  inefficient.	  In	  addition,	  periods	  of	  exclusivity	  delay	  the	  creation	  of	  generic	  drugs,	  costing	  consumers	  hundreds	  of	  millions	  of	  dollars	  (Greenwood,	  2011).	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Government	  funded	  or	  mandate	  research	  The	  most	  direct	  approach	  to	  closing	  the	  information	  gap	  would	  be	  for	  the	  government	  to	  fund	  or	  mandate	  such	  research.	  There	  are	  various	  examples	  in	  the	  pediatric	  arena.	  For	  one,	  in	  addition	  to	  the	  exclusivity	  provision,	  BPCA	  requires	  that	  NIH	  publish	  a	  list	  of	  the	  highest	  priority	  diseases	  or	  conditions	  in	  which	  medication-­‐related	  knowledge	  gaps	  negatively	  affect	  children	  who	  are	  living	  with	  these	  conditions.	  Funds	  are	  then	  awarded	  to	  qualified	  entities	  to	  enable	  them	  to	  conduct	  drug	  studies	  or	  other	  research	  on	  the	  issues	  on	  the	  list	  (NIH,	  2011).	  Adopting	  this	  strategy	  may	  be	  a	  more	  sensible	  approach	  to	  closing	  the	  information	  gap	  regarding	  drug	  safety	  and	  efficacy	  for	  pregnant	  women	  and	  fetuses.	  Although	  it	  would	  require	  the	  appropriation	  of	  a	  significant	  amount	  of	  funds,	  some	  believe	  that	  the	  government	  would	  be	  able	  to	  conduct	  research	  for	  less	  than	  it	  would	  spend	  to	  incentivize	  it	  (Greenwood,	  2011).	  Other	  advantages	  include	  that	  the	  government	  would	  not	  have	  to	  factor	  in	  whether	  or	  not	  drugs	  are	  on	  patent	  or	  in	  an	  exclusivity	  period.	  In	  addition,	  the	  government	  would	  be	  free	  to	  consider	  whether	  it	  would	  be	  preferable	  to	  perform	  basic	  research	  into	  pregnancy’s	  pharmacokinetic	  and	  –dynamic	  effects	  or	  into	  the	  mechanisms	  of	  teratogenicity	  (Greenwood,	  2011).	  
The	  government	  could	  also	  require,	  in	  appropriate	  cases,	  drug	  manufacturers	  fund	  maternal-­‐fetal	  medication	  research.	  In	  the	  pediatric	  arena,	  the	  Pediatric	  Research	  Equity	  Act	  (PREA)	  requires,	  as	  a	  condition	  of	  FDA	  approval	  of	  a	  new	  drug	  application,	  indication,	  dosage,	  dosing	  regimen,	  or	  route	  of	  administration,	  that	  it	  first	  be	  studied	  in	  children	  (Greenwood,	  2011).	  The	  Act	  also	  gives	  the	  FDA	  the	  power	  to	  require	  that	  a	  manufacturer	  study	  one	  of	  its	  already-­‐approved	  drugs	  if	  the	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manufacturer	  declines	  to	  study	  the	  drug	  voluntarily	  and	  the	  Foundation	  for	  the	  National	  Institute	  of	  Health	  lacks	  funds	  to	  conduct	  the	  study,	  if	  one	  of	  the	  following	  circumstances	  are	  met:	  
(1) The	  drug	  is	  taken	  by	  a	  substantial	  number	  of	  children	  for	  the	  labeled	  
indications	  and	  adequate	  labeling	  could	  benefit	  pediatric	  patients;	  
(2) There	  is	  reason	  to	  believe	  the	  drug	  would	  be	  a	  meaningful	  
improvement	  over	  existing	  therapies	  for	  children	  for	  one	  of	  the	  
labeled	  indications;	  or	  
(3) The	  absence	  of	  adequate	  labeling	  could	  pose	  a	  risk	  to	  pediatric	  
patients	  (Greenwood,	  2011,	  p320).	  
	  Pregnant	  women	  and	  fetuses	  would	  benefit	  from	  the	  extension	  of	  PREA	  to	  address	  the	  maternal-­‐fetal	  medication	  information	  gap.	  Even	  if	  PREA	  is	  not	  extended,	  FDA	  should	  make	  full	  use	  of	  its	  powers	  to	  require,	  where	  appropriate,	  the	  creation	  of	  a	  pregnancy	  exposure	  registry	  and	  a	  plan	  for	  post-­‐marketing	  surveillance	  as	  conditions	  of	  drug	  approval.	  The	  FDA	  defines	  pregnancy	  exposure	  registries	  as	  prospective	  observational	  studies	  that	  collect	  information	  on	  women	  who	  take	  medications	  and	  vaccines	  during	  pregnancy	  (FDA,	  2012).	  Currently	  registries	  exist	  in	  a	  non-­‐cohesive	  patchwork.	  Furthermore	  should	  make	  full	  use	  of	  it	  power	  (authorized	  by	  FDA	  Amendments	  Act)	  to	  require	  post-­‐marketing	  studies	  and	  clinical	  trials	  under	  certain	  circumstances	  (Greenwood,	  2011).	  
In	  2009,	  the	  FDA	  announced	  the	  creation	  of	  the	  Medication	  Exposure	  in	  Pregnancy	  Risk	  Evaluation	  Program	  (MEPREP).	  Although	  the	  program	  is	  yet	  to	  be	  rolled	  out,	  it	  is	  charged	  with	  funding	  and	  conducting,	  in	  collaboration	  with	  private	  researchers,	  research	  that	  examines	  the	  effects	  of	  prescription	  medications	  used	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during	  pregnancy	  (Greenwood,	  2011).	  	  Another	  example	  of	  a	  promising	  public-­‐private	  partnership	  is	  the	  FDA’s	  Sentinel	  System.	  Section	  905	  of	  the	  FDA	  Amendments	  Act	  requires	  that	  the	  FDA	  establish	  a	  post-­‐market	  risk	  identification	  and	  analysis	  system	  to	  link	  and	  analyze	  safety	  data	  from	  multiple	  sources	  (Greenwood,	  2012).	  Once	  in	  place,	  this	  system	  has	  the	  potential	  to	  generate	  a	  multitude	  of	  valuable	  information	  about	  maternal-­‐fetal	  medication	  risk.	  	  
Attempts	  to	  eliminate	  the	  liability	  barrier	  facing	  drug	  manufacturers	  are	  unlikely	  to	  be	  successful,	  while	  offering	  periods	  of	  exclusivity	  as	  incentives	  to	  private	  sector	  research	  is	  thought	  to	  be	  largely	  inefficient.	  On	  the	  other	  hand,	  increased	  funding	  of	  public	  –private	  partnerships	  like	  MEDPREP	  and	  FDA’s	  Sentinel	  System,	  combined	  with	  legislation	  that	  mandates	  that	  drug	  companies	  research	  their	  products	  not	  only	  in	  children	  but	  in	  pregnant	  women	  and	  fetuses	  as	  well,	  are	  promising	  approaches	  to	  closing	  the	  information	  gap.	  
Conclusion	  
Over	  the	  decades,	  considerable	  progress	  has	  been	  made	  with	  regards	  to	  the	  inclusion	  of	  women	  in	  biomedical	  research.	  This	  paper,	  and	  many	  before	  it	  have	  drawn	  attention	  the	  continued	  exclusion	  of	  pregnant	  women,	  and	  the	  consequences	  of	  such	  exclusion.	  This	  paper	  went	  one	  step	  further	  to	  show	  that	  a	  sub-­‐population,	  low-­‐income	  persons	  of	  color,	  is	  disproportionately	  burdened	  by	  the	  insufficient	  inclusion	  of	  pregnant	  women	  and	  the	  resulting	  information	  gap.	  In	  looking	  ahead,	  the	  movement	  towards	  the	  responsible	  inclusion	  of	  pregnant	  women	  in	  biomedical	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